Skip to search formSkip to main contentSkip to account menu

ropinirole

Known as: Ropinirol, 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone, ropinirole [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

12 relations
24 HR ropinirole 12 MG Extended Release Oral Tablet [Requip]24 HR ropinirole 6 MG Extended Release Oral TabletDrug AllergyParkinson Disease

Broader (3)

Antiparkinson AgentsDopamine AgonistsIndoles

Narrower (5)

RequipRopinirole hydrochlorideSK&F 101468ropinirole 0.25 MG Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders Na Ye,† John L. Neumeyer,‡ Ross J… 
Review
2011
Review
2011
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease… 
Highly Cited
2007
Highly Cited
2007
Ropinirole 24-hour prolonged release
Objective: To evaluate the efficacy of ropinirole 24-hour prolonged release (ropinirole 24-hour) as an adjunct to levodopa in… 
Highly Cited
2007
Highly Cited
2007
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole
Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate… 
Review
2006
Review
2006
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Highly Cited
2004
Highly Cited
2004
Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome.
STUDY OBJECTIVES Polysomnographic study evaluating the efficacy of ropinirole for the treatment of patients with restless legs… 
Review
2000
Review
2000
Clinical Pharmacokinetics of Ropinirole
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson’s disease. When taken… 
Highly Cited
1999
Highly Cited
1999
Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Highly Cited
1998
Highly Cited
1998
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset
In contrast to levodopa (L‐dopa), de novo administration of the D2‐like receptor agonist bromocriptine to patients with Parkinson… 
Highly Cited
1997
Highly Cited
1997
Ropinirole for the treatment of early Parkinson's disease
A prospective, randomized, placebo-controlled, double-blind, parallel-group, 6-month study assessed the efficacy and safety of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)